Ignite Creation Date:
2024-05-06 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06140836
Status:
RECRUITING
Last Update Posted:
2024-06-25
First Post:
2023-11-15
Brief Title:
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor TKI-naïve ROS1-positive Non-Small Cell Lung Cancer NSCLC TRIDENT-3
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-21
Start Date Type:
ACTUAL
Primary Completion Date:
2029-02-26
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-01-27
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-15
First Submit QC Date:
November 15 2023
Study First Post Date:
2023-11-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-22
Last Update Post Date:
2024-06-25
Last Update Post Date Type:
ACTUAL